Literature DB >> 23294015

Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy.

Régis Peffault de Latour1, Aliénor Xhaard, Véronique Fremeaux-Bacchi, Paul Coppo, Anne Marie Fischer, Dominique Helley, Gérard Socié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23294015     DOI： 10.1111/bjh.12202

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  23 in total

1.  Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.

Authors:  Johann Castañeda-Sanabria; David Hajage; Melisande Le Jouan; Anne Perozziello; Florence Tubach
Journal:  Eur J Clin Pharmacol       Date:  2016-02-26       Impact factor: 2.953

Review 2.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

3.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

4.  Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.

Authors:  Jiaqian Qi; Jie Wang; Jia Chen; Jian Su; Yaqiong Tang; Xiaojin Wu; Xiao Ma; Feng Chen; Changgeng Ruan; X Long Zheng; Depei Wu; Yue Han
Journal:  Ann Hematol       Date:  2017-08-11       Impact factor: 3.673

5.  Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia.

Authors:  M Okano; N Sakata; S Ueda; T Takemura
Journal:  Bone Marrow Transplant       Date:  2014-05-12       Impact factor: 5.483

6.  Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT.

Authors:  Hiroyuki Matsui; Yasuyuki Arai; Hiroharu Imoto; Takaya Mitsuyoshi; Naoki Tamura; Tadakazu Kondo; Junya Kanda; Takayuki Ishikawa; Kazunori Imada; Yasunori Ueda; Yusuke Toda; Naoyuki Anzai; Kazuhiro Yago; Masaharu Nohgawa; Akihito Yonezawa; Hiroko Tsunemine; Mitsuru Itoh; Kazuyo Yamamoto; Masaaki Tsuji; Toshinori Moriguchi; Akifumi Takaori-Kondo
Journal:  Blood Adv       Date:  2020-07-14

Review 7.  An international consensus approach to the management of atypical hemolytic uremic syndrome in children.

Authors:  Chantal Loirat; Fadi Fakhouri; Gema Ariceta; Nesrin Besbas; Martin Bitzan; Anna Bjerre; Rosanna Coppo; Francesco Emma; Sally Johnson; Diana Karpman; Daniel Landau; Craig B Langman; Anne-Laure Lapeyraque; Christoph Licht; Carla Nester; Carmine Pecoraro; Magdalena Riedl; Nicole C A J van de Kar; Johan Van de Walle; Marina Vivarelli; Véronique Frémeaux-Bacchi
Journal:  Pediatr Nephrol       Date:  2015-04-11       Impact factor: 3.714

Review 8.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

Review 9.  Novel immunosuppressive agents in kidney transplantation.

Authors:  Karen L Hardinger; Daniel C Brennan
Journal:  World J Transplant       Date:  2013-12-24

10.  Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.

Authors:  Michelle Schoettler; Leslie Lehmann; Anran Li; Clement Ma; Christine Duncan
Journal:  Biol Blood Marrow Transplant       Date:  2019-01-11       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.